CellCure

Executive Summary

CellCure is a UK-based biotechnology company pioneering cell-based therapies for degenerative diseases, with a primary focus on ophthalmology. The company is developing stem cell-derived retinal pigment epithelium (RPE) cells to treat age-related macular degeneration (AMD), a leading cause of blindness. By replacing damaged RPE cells, CellCure aims to restore vision in patients with advanced dry AMD. The company has raised over $140 million in funding and is currently in Phase 1 clinical development. Its approach leverages induced pluripotent stem cell technology to generate RPE cells that can be implanted into the retina, offering a potentially one-time curative treatment. The market opportunity is substantial, with millions of AMD patients worldwide lacking effective therapies. CellCure's preclinical data have shown promising safety and efficacy, and the company is now progressing toward human proof-of-concept studies. If successful, CellCure could address a significant unmet medical need and capture a large share of the ophthalmic regenerative medicine market, which is projected to grow rapidly. The company's strong intellectual property portfolio and experienced management team further bolster its position. However, as a Phase 1 stage company, CellCure faces typical risks including clinical trial outcomes, regulatory hurdles, and manufacturing scale-up challenges.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical trial interim data readout60% success
• Q2 2027FDA IND clearance for next-generation RPE therapy70% success
• H2 2026Strategic partnership or licensing deal with a large pharma50% success